The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Your browser doesn't assist the audio ingredient.John V. Heymach, MD, PhD, summarizes case for a 62-year-old affected person with non–small cell lung most...
GE HealthCare Applied sciences’ Inc. GEHC MIM Software program not too long ago launched the MIM Symphony HDR Prostate to assist excessive dose-rate (HDR)...
Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: classes from mouse fashions, implications for people. Blood. 2012;120:5118–27.Article
...
